Boltwood Capital Management decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 4.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 72,193 shares of the biopharmaceutical company’s stock after selling 3,465 shares during the period. Pfizer comprises 2.2% of Boltwood Capital Management’s portfolio, making the stock its 10th biggest position. Boltwood Capital Management’s holdings in Pfizer were worth $3,151,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Moody National Bank Trust Division grew its stake in shares of Pfizer by 0.7% during the fourth quarter. Moody National Bank Trust Division now owns 515,846 shares of the biopharmaceutical company’s stock valued at $22,517,000 after purchasing an additional 3,681 shares during the last quarter. Advocacy Wealth Management Services LLC grew its stake in shares of Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 258 shares during the last quarter. Indiana Trust & Investment Management CO grew its stake in shares of Pfizer by 2.9% during the fourth quarter. Indiana Trust & Investment Management CO now owns 22,475 shares of the biopharmaceutical company’s stock valued at $981,000 after purchasing an additional 635 shares during the last quarter. Bath Savings Trust Co grew its stake in shares of Pfizer by 2.7% during the fourth quarter. Bath Savings Trust Co now owns 16,953 shares of the biopharmaceutical company’s stock valued at $740,000 after purchasing an additional 448 shares during the last quarter. Finally, Silverleafe Capital Partners LLC grew its stake in shares of Pfizer by 17.5% during the fourth quarter. Silverleafe Capital Partners LLC now owns 54,652 shares of the biopharmaceutical company’s stock valued at $2,386,000 after purchasing an additional 8,138 shares during the last quarter. 68.44% of the stock is owned by institutional investors.
Shares of PFE stock opened at $42.35 on Friday. Pfizer Inc. has a 52-week low of $34.32 and a 52-week high of $46.47. The company has a market capitalization of $251.03 billion, a price-to-earnings ratio of 14.12, a price-to-earnings-growth ratio of 2.42 and a beta of 0.76. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. The firm had revenue of $13.98 billion for the quarter, compared to analysts’ expectations of $13.92 billion. During the same period last year, the firm earned $0.62 earnings per share. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.86 earnings per share for the current year.
Pfizer announced that its board has authorized a stock buyback program on Friday, December 14th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase up to 3.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.
Several research firms have recently commented on PFE. Citigroup reissued a “neutral” rating and set a $41.00 price target on shares of Pfizer in a research note on Wednesday, February 20th. Cantor Fitzgerald reissued a “buy” rating and set a $53.00 price target on shares of Pfizer in a research note on Tuesday, February 19th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Thursday, January 31st. Credit Suisse Group raised shares of Pfizer from a “neutral” rating to an “outperform” rating in a research note on Thursday, January 31st. Finally, Zacks Investment Research cut shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $44.89.
In other Pfizer news, EVP Douglas M. Lankler sold 5,000 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $42.75, for a total value of $213,750.00. Following the sale, the executive vice president now directly owns 83,592 shares in the company, valued at $3,573,558. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Rady A. Johnson sold 8,700 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $41.13, for a total transaction of $357,831.00. Following the completion of the sale, the insider now owns 59,797 shares in the company, valued at $2,459,450.61. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 317,526 shares of company stock worth $13,704,089. Insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Boltwood Capital Management Reduces Stake in Pfizer Inc. (PFE)” was posted by Zolmax and is the sole property of of Zolmax. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://zolmax.com/investing/boltwood-capital-management-reduces-stake-in-pfizer-inc-pfe/2981407.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: What are municipal bonds?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.